Advertisement
Pasithea Announces Receipt Of FDA Response Of Pre-IND Meeting For PAS-004 Clinical Development
(RTTNews) - Biotechnology company Pasithea Therapeutics Corp. (KTTA) announced Wednesday receipt of written responses to questions submitted for a Type 2 pre-Investigational New Drug Application (IND) meeting with the U.S. Food and Drug Administration (FDA) regarding clinical development plan for PAS-004.
The FDA's positive feedback and guidance include a recommendation to begin dosing in patients who will benefit from treatment rather than in healthy volunteers. PAS-004 was granted orphan drug designation for the treatment of NF1 in November 2020.
The company said it will begin dosing as early as the first quarter of 2024 following acceptance of the IND by the FDA.
PAS-004 has been tested in a range of mouse models of various diseases and has completed preclinical testing and animal toxicology studies to support an IND application with the FDA that it plans to submit in the fourth quarter of 2023.
Indian Rupee Falls To 4-day Low Against U.S. Dollar
CAC Moderately Higher As Stocks Recover From Recent Setback
DAX Up 1.1% As Stocks Rebound From Recent Losses
Sensex, Nifty Snap Two-day Losing Streak As Focus Shifts To RBI
European Shares Tick Higher In Cautious Trade
Asian Shares Mixed As US Jobs Data Fuels Rate Cut Bets
Yen Advances Against Majors
